About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, TPA, (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

April 10

Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients View Release

March 14

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma View Release

March 6

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy View Release

» Read Latest News